<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667485</url>
  </required_header>
  <id_info>
    <org_study_id>15878B</org_study_id>
    <secondary_id>AVF4180s</secondary_id>
    <nct_id>NCT00667485</nct_id>
  </id_info>
  <brief_title>Rapamycin Plus Bevacizumab in Advanced Cancers</brief_title>
  <official_title>A Phase I Study of Rapamycin (Sirolimus) With Bevacizumab in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this trial is to determine the toxicity and maximum dose of rapamycin and
      bevacizumab given together to subjects with advanced cancers. This study will also look at
      the pharmacokinetics and antitumor activity of the combination.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rapamycin (liquid) taken weekly and Bevacizumab (IV infusion ) once every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Daily oral rapamycin (tablets) and Bevacizumab (IV infusion)once every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (liquid)</intervention_name>
    <description>Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)</description>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <other_name>sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks</description>
    <arm_group_label>Weekly Rapamcyin</arm_group_label>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin (Tablets)</intervention_name>
    <description>Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg</description>
    <arm_group_label>Daily Rapamycin</arm_group_label>
    <other_name>sirolimus</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic or unresectable solid tumor for which standard treatments do not exist or
             are no longer effective

          -  Performance status of 0-1

          -  Measurable or non-measurable disease

          -  Life expectancy of at least 12 weeks

          -  No anticipated need of other cancer treatments within the next 4 weeks

          -  18 years or older

          -  Negative pregnancy test for women able to have children, agreement to use a medically
             accepted birth control method while receiving the study drugs and for at least 2 weeks
             after stopping, not breast feeding

          -  Ability to understand and willingness to sign a written informed consent document

          -  No evidence of bleeding diathesis

          -  Patients without lung cancer receiving anti-coagulation treatment can participate

          -  Adequate organ and marrow function:

               -  ALT and AST less than or equal to 2.5 times the institutional ULN (less than 5
                  times for patients with liver involvement)

               -  hemoglobin at least 9g/dL

               -  absolute neutrophil count at least 1,500/µL

               -  platelets at least 100,000/µL

               -  total bilirubin less than or equal to 1.5 times the institutional ULN

               -  creatinine less than or equal to 1.5 times the institutional ULN

        Exclusion Criteria:

          -  Prior treatment with both bevacizumab and an mTOR inhibitor is not allowed. Prior
             treatment with both bevacizumab OR mTOR inhibitor (including rapamycin) is allowed.
             Patients who had a grade 3 or greater side effect with either bevacizumab or an mTOR
             inhibitor cannot take part in this study.

          -  Chemotherapy or Immunotherapy within the 4 weeks of study start

          -  Radiotherapy within 14 days of study start

          -  Cannot be receiving any other investigational drugs or any other cancer treatments
             while on study (with the exception of androgen ablating agents for patients with
             prostate cancer).

          -  Patients with squamous non-small cell lung cancer (NSCLC)

          -  Patients with lung cancer or lung metastases:

               -  on full dose anticoagulation

               -  taking 325mg aspirin per day

               -  on non-steroidal anti-inflammatory agents

          -  HIV positive patients receiving combination anti-retroviral therapy are excluded due
             to potential for serious infections while taking marrow suppressing agents

          -  Ongoing illness or medical exclusions, including but not limited to:

               -  active or ongoing infection

               -  symptomatic congestive heart failure

               -  uncontrolled hypertension despite optimal medical management

               -  cardiac arrhythmia except paroxysmal atrial fibrillation

               -  psychiatric illness/social situations that would limit compliance with study
                  requirements

               -  history of organ allograft, bone marrow or peripheral blood stem cell transplant

               -  known or suspect allergy to bevacizumab or rapamycin

               -  seizure disorder treated with steroid or anticonvulsant therapy

               -  thrombotic or embolic events within 6 months of starting study

               -  pulmonary hemorrhage/bleeding within 12 weeks of starting study (grade 3 event
                  within 4 weeks of first dose of drug). Patients with a history of pulmonary
                  hemorrhage/bleeding cannot be on full dose anticoagulation.

               -  pulmonary fibrosis or interstitial lung disease

               -  serious non-healing wound, ulcer or bone fracture

               -  Major surgery, open biopsy or a traumatic injury within 4 weeks of starting study
                  drug

               -  anticipated need for major surgery while on-study

               -  current use of any herbal supplements or rifampin (rifampicin)

               -  prior history of hypertensive crisis or hypertensive encephalopathy

               -  history of myocardial infarction or unstable angina within 6 months of starting
                  study

               -  known CNS disease

               -  significant vascular disease

               -  symptomatic peripheral vascular disease

               -  evidence of bleeding diathesis or coagulopathy

               -  core biopsy or other minor surgical procedure (except placement of vascular
                  access device) within 7 days of starting study

               -  history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
                  abscess within 6 months of study start

               -  proteinuria at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezra Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2008</study_first_submitted>
  <study_first_submitted_qc>April 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <last_update_submitted>January 16, 2014</last_update_submitted>
  <last_update_submitted_qc>January 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

